November 8, 2023
(press release)
–
Florham Park, NJ – November 8, 2023 - IFF’s and BASF’s Pharma Solutions divisions have joined forces in a collaboration to onboard IFF’s leading product brands in pharmaceutical excipients on BASF’s Virtual Pharma Assistant platform – ZoomLab™. The platform is a science-based digital tool designed to rapidly and accurately predict the best excipients needed for the development of new pharmaceutical formulations to help overcome formulation challenges. The collaboration between IFF and BASF aligns with the companies’ shared values on customer-centricity and the goal to bring a seamless digital experience to more formulators worldwide. Powered by BASF’s proprietary algorithm, ZoomLab™ allows formulators to accelerate formulation design by predicting the most effective excipients to match a given active pharmaceutical ingredient. It also allows them to make customizations, offering a range of ingredients to choose from – including IFF’s renowned high-quality excipients. In the first phase of the collaboration, IFF’s product line Avicel® microcrystalline cellulose (MCC) and super disintegrant Ac-Di-Sol® croscarmellose sodium will be available to users in ZoomLab™ Excipient Database and throughout the various ZoomLab™ modules. Formulators and ZoomLab™ users will benefit through this broadened access to excipients to solve their formulation challenges. “Our collaboration with IFF aligns well with our commitment to provide exceptional value to our customers through our digital Virtual Pharma Assistants. Including IFF products within ZoomLab™ underlines our ambition to continuously develop ZoomLab™ into the leading industry platform giving users access to a broad range of excipients and make it even easier to create formulations quickly,” said Jeffrey DeAlmeida, senior vice president, BASF Pharma Solutions and Nutrition and Health, Americas. “We will continue to deepen our collaboration on ZoomLab™ in the future including more content and features for users.” “At IFF, we apply a customer-centric approach to problem-solving throughout the drug development process. We are committed to being the partner our customers can count on, and now – thanks to our exciting collaboration with BASF on ZoomLab™ – we are helping even more customers innovate and overcome their formulation challenges,” said Angela Strzelecki, president, IFF Pharma Solutions. “The addition of our renowned ingredients into this platform enhances the ability of ZoomLab™ to predict the best formulations and accelerates the launch of more innovative products across the global pharmaceutical market which is good for manufacturers and patients around the world.” About ZoomLab™ ZoomLab™ is a science-based digital tool that allows formulators to predict their next drug’s starting formulations and solve other formulation challenges. ZoomLab™ is available online. Learn more about ZoomLab™ on Zoomlab™ (pharma.basf.com). About BASF At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. More than 111,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio comprises six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF generated sales of €87.3 billion in 2022. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the United States. Further information at www.basf.com. About IFF At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn P-23-352
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
